Skip to content

Contact +44 (0) 20 7060 7474 email us

Biotechnology

Medical Nanotechnology Markets

 

Publication Date September 2008
Publisher TriMark Publications
Product Type Report
Pages 183
ISBN Number not applicable
Product Code TRI00086

Price

£2,245.00
approximately: $3,399 | €2,506

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Nanotechnology has reached critical mass. Nowhere is this more evident than in medicine. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare. According to U.S. National Science Foundation estimates, by 2015 the annual global market for nano-related goods and services will top $1 trillion, thus making it one of the fastest-growing industries in history. Assuming that these figures prove to be accurate, nanotechnology will emerge as a larger economic force than the combined telecommunications and information technology industries at the beginning of the technology boom of the late 1990s. This TriMark Publications report covers the specific segments of the medical nanotechnology markets, with particular emphasis on those segments where this emerging technology is or shows the potential to be most impactful. Nanotechnology, a field of science and technology that aims to control matter at the atomic, molecular and macromolecular level, potentially has far-reaching and paradigm-shifting implications for biology, drug discovery and medical technologies. The discipline has already yielded healthcare discoveries that have been used for drug delivery and diagnostic purposes. In this study, we describe various nanotechnologies under development for biological and medical purposes and assess their potential. Moreover, this analysis is arranged to provide an overview of the regulatory issues faced by the medical nanotechnology industry and focuses on how specific segments within the industry are poised for high future growth.

Contents

  • 1 Overview
    • 1.1 Statement Of Report
    • 1.2 About This Report
    • 1.3 Scope Of The Report
    • 1.4 Methodology
    • 1.5 Executive Summary
  • 2 Medical Products (Drugs, Devices And Nutraceuticals) Nanotechnology Markets
    • 2.1 Background
    • 2.2 Market Calculations
    • 2.3 Market Demands
    • 2.4 Market Overview
      • 2.4.1 The Role Of Nanotechnologies In Medicine
      • 2.4.2 Nanotechnology Sector Challenges
      • 2.4.3 Nanotechnology Sector Drivers
      • 2.4.4 Nanotechnology Sector Restraints
    • 2.5 Nanotechnology Medical Product Market Segments
      • 2.5.1 Overview
      • 2.5.2 World Markets
      • 2.5.3 U.S. Market
      • 2.5.4 European Market
      • 2.5.5 Japanese Market
      • 2.5.6 Asian Market
      • 2.5.7 Middle East
      • 2.5.8 Row
  • 3 Medical And Life Science Nanotechnology Markets
    • 3.1 Nano-Particles
    • 3.2 Market For Nano-Particles In Life Sciences And Medicine
      • 3.2.1 Key Players
      • 3.2.2 Application Manufacturers
    • 3.3 Dendrimers
      • 3.3.1 Pamam Dendrimers
      • 3.3.2 Market For Nanocapsules In Life Sciences And Healthcare
      • 3.3.3 Key Players
    • 3.4 Market For Nanoporous And Nanostructured Materials In Life Sciences And Healthcare
      • 3.4.1 Key Players
      • 3.4.2 Nanofiltration
    • 3.5 Nanodevices, Nanosensors And Quantum Dots
      • 3.5.1 Sector Overview
      • 3.5.2 Market For Quantum Dots In Life Sciences And Medicine
      • 3.5.3 Commercial Applications For Quantum Dots
      • 3.5.4 Key Players
      • 3.5.5 Nanomaterials Suppliers
      • 3.5.6 Application Manufacturers
    • 3.6 Nanocoatings
    • 3.7 Nanocomposites
    • 3.8 Nanoarrays
      • 3.8.1 Bead Nanoarrays: A High-Sensitivity Detection System
    • 3.9 Fullerenes
      • 3.9.1 Key Applications And Market Opportunities
      • 3.9.2 Medical Market Uses For Carbon Nanotubes
      • 3.9.3 Key Players, Including Application Manufacturers, End Users And Nanomaterials Suppliers
    • 3.10 Liposome-Like Nano-Particles
      • 3.10.1 Nanostructured Lipid Carriers
      • 3.10.2 Dauxoxome Liposomal Formulation
    • 3.11 Nanosensors
      • 3.11.1 Microcantilever Sensors And Photonic Sensors
      • 3.11.2 Field-Effect Nanoplate Devices
      • 3.11.3 Electrochemical-Transducing Electrode Systems
  • 4 Technology Issues
    • 4.1 Nanotechnology In Drug Delivery And Development
      • 4.1.1 Drug Delivery Using Nanotechnology
      • 4.1.2 Design Of Nanotechnology-Based Drug Delivery Systems
      • 4.1.3 Using Magnetic Nano-Particles In Targeted Drug Delivery
      • 4.1.4 Cancer Drug Delivery
      • 4.1.5 Nano-Particle-Mediated Delivery Of Sirna
      • 4.1.6 Targeting Angiogenesis With Nano-Particles
      • 4.1.7 Nanosystems And Inflammation
      • 4.1.8 The Chiral Drug Development Process
      • 4.1.9 Reasons Why The Drug Delivery Market Is Rapidly Expanding
    • 4.2 Categories Of Medical Nanotechnology Products
      • 4.2.1 Surgical Steel Devices
      • 4.2.2 Contrast-Enhancing Agents For Mri (Magnetic Resonance Imaging)
      • 4.2.3 Wound Dressings / Anti-Microbial Textiles
      • 4.2.4 Nanocoated Surgical Blades
      • 4.2.5 Suture Needles And Microneedles
      • 4.2.6 Catheters For Minimally-Invasive Surgery
      • 4.2.7 Optical Nanosurgery
      • 4.2.8 Nanocoated Or Nanocontoured Implant Surfaces
    • 4.3 Biosensors And Biodetection
      • 4.3.1 Cantilever Arrays
      • 4.3.2 Nanosensors
      • 4.3.3 Optical Sensors
      • 4.3.4 Nano-Particle Sensors And Detectors
      • 4.3.5 In Vitro Diagnostics
      • 4.3.6 Imaging, In Vivo Diagnosis And Theranostics
    • 4.4 Vaccinesvirus-Like Particles (Vlps)
    • 4.5 Transdermal Drug Delivery
    • 4.6 Phage Microarrays
    • 4.7 Neuroscience
    • 4.8 Nanotechnology Materials For Medical Products
      • 4.8.1 Dental Materials
      • 4.8.2 Bone Replacement
      • 4.8.3 Contact Lenses
    • 4.9 New Drug Development
    • 4.10 Future Directions
      • 4.10.1 Sources Of Nano Development
      • 4.10.2 Commercialization
      • 4.10.3 Current/Pending Clinical Trials On New Products And Emerging Technologies
      • 4.10.4 Future Directions
    • 4.11 Key Technology Findings For Medical Uses Of Nanotechnology
  • 5 Business Trends
    • 5.1 Market Forces
      • 5.1.1 Market Drivers
      • 5.1.2 Market Restraints
      • 5.1.3 Medical / Clinical Studies
      • 5.1.4 Demographics
    • 5.2 Market Prospects
    • 5.3 Marketing And Distribution
    • 5.4 Competitive Landscape
    • 5.5 Business Developments
      • 5.5.1 Drug Pedigrees
    • 5.6 Acquisitions And Partnerships
    • 5.7 Key Players
    • 5.8 Patent Climate
    • 5.9 Investment Climate
      • 5.9.1 U.S. Government
      • 5.9.2 Europe
    • 5.10 Venture Capital Environment
      • 5.10.1 Medical And Health Nanotech Venture Companies
      • 5.10.2 Pharma And Biotech Nanotech Venture Companies
    • 5.11 Business Strategies For Medical Nanotechnology
    • 5.12 Nanotechnology Questions
      • 5.12.1 What Are The Near-Term Business Opportunities In The Medical Nanotechnology Markets?
      • 5.12.2 What Are The Business Models Currently Used By Companies In The Medical Nanotechnology Markets?
      • 5.12.3 How Will Manufacturers, Researchers, Physicians, Patients And Payers Influence The Medical Nanotechnology Markets?
      • 5.12.4 What Are The Drivers And Bottlenecks Influencing The Medical Nanotechnology Markets?
      • 5.12.5 What Are The Current And Emerging Technologies Used In The Medical Nanotechnology Markets?
      • 5.12.6 Who Holds The Proprietary Rights To The Medical Nanotechnology Markets, Especially In Such A Multidisciplinary Environment?
      • 5.12.7 What Are Current Applications Of These Technologies?
      • 5.12.8 What Regulatory Processes Must Medical Nanotechnology Undergo In The U.S., Japan And Europe?
      • 5.12.9 How Will New Or Emerging Medical Nanotechnologies Change Treatment And Payment Paradigms?
      • 5.12.10 How Will Medical Nanotechnologies Reduce Adverse Clinical Reactions And Decrease Total Patient Care Cost?
      • 5.12.11 How Will Medical Nanotechnology Reduce Healthcare Expenditures?
      • 5.12.12 How Will Medical Nanotechnology Decrease Patient Diagnostic Testing Costs?
      • 5.12.13 What Is The Role Of Nanotechnology In Drug Development?
      • 5.12.14 Which Medical Nanotechnology Product Categories Are Driving Growth?
      • 5.12.15 How Are Biomarkers Being Developed Using Nanotechnology?
      • 5.12.16 What Companies Are Developing Nanotechnology Drug Delivery Systems?
      • 5.12.17 How Are Nano-Optical Tagging Technologies Used In Animal Drug Safety Assessment Studies?
      • 5.12.18 What Nanotechnology Platforms Are Being Used In Point Of Care Diagnostic Testing?
  • 6 Technology Assessment
    • 6.1 Current Technologies For Nano
      • 6.1.1 Nanodiagnostics
      • 6.1.2 Competitive Analysis Of Nano-Particle Assays
      • 6.1.3 In Vivo Imaging
      • 6.1.4 In Vitro Clinical Diagnostics
    • 6.2 Future Technologies
    • 6.3 Technology Accelerators, Roadblocks And Challenges
      • 6.3.1 Technology Accelerators
      • 6.3.2 Technology Roadblocks And Challenges
      • 6.3.3 Public Awareness
    • 6.4 Nanotechnology Product Trends And New Concepts For Medical Applications
      • 6.4.1 Market Trendsdiagnostics
      • 6.4.2 Market Trendstherapies
      • 6.4.3 Market Trendspreventive And Other
      • 6.4.4 Nanofibers In Medical Applications
      • 6.4.5 Dental Applications
      • 6.4.6 Optical Applications
    • 6.5 Production Methods
  • 7 Medical Nanotechnology Market Regulation And Reimbursement
    • 7.1 Market Segments
      • 7.1.1 Diagnostics
      • 7.1.2 Therapies
      • 7.1.3 Preventive
    • 7.2 Customer Needs
    • 7.3 Competitor Analysis
    • 7.4 Pricing Pressures
    • 7.5 U.S. Medicare And Other Government Agency Issues
    • 7.6 Third-Party Reimbursement
    • 7.7 Regulatory Trends
      • 7.7.1 Regulatory Policy For Nanotechnology Drugs And Medical Devices
      • 7.7.2 Current Good Manufacturing Practices (Cgmps)
      • 7.7.3 Current Progress
      • 7.7.4 Future Regulatory Trends
      • 7.7.5 Key Issues
      • 7.7.6 Labeling Requirements
    • 7.8 Government Initiatives
      • 7.8.1 Nni Research Centers
      • 7.8.2 Nni Centers And Networks Of Excellence
      • 7.8.3 Fdas Nanotechnology Task Force
      • 7.8.4 Dutch Government Nano Action Plan
      • 7.8.5 Other Research Centers
    • 7.9 Medical Regulatory And Cgmps Issues
    • 7.10 New Technology Concerns
    • 7.11 Use Environment
      • 7.11.1 Cancer
      • 7.11.2 Medical Review
    • 7.12 Risk Assessment
      • 7.12.1 Risk Management (Iso 14971:2007)
      • 7.12.2 Toxicology Assessment
      • 7.12.3 Safety Evaluation
    • 7.13 Cautions For Medical Nanotechnology Platforms
      • 7.13.1 Etuc Precautionary Principle Applied To Nanotechnologies
      • 7.13.2 Possible Risks To Human Health From Nanotechnology Products
  • 8 Corporate Profiles
    • 8.1 Abbott Laboratories
    • 8.2 Abraxis Biosciences
      • 8.2.1 Nda Pipeline
    • 8.3 Aduro Biotech
    • 8.4 Advanced Magnetics (Amag Pharmaceuticals)
    • 8.5 Alnis Biosciences
    • 8.6 App Pharmaceuticals
    • 8.7 Arrowhead Research Corporation
    • 8.8 Baxter International
    • 8.9 Bristol-Myers Squibb
    • 8.10 Caliper
    • 8.11 Capsulution Nanoscience Ag
    • 8.12 Cytrx Corporation
    • 8.13 Dendritech, Inc
    • 8.14 Dendritic Nanotechnologies, Inc
    • 8.15 Dow Chemical
    • 8.16 Dupont
      • 8.16.1 The Framework
    • 8.17 Elan Drug Delivery (See Also Bristol-Myers Squibb)
    • 8.18 Evident Technologies
    • 8.19 Evolved Nanomaterial Sciences (Ens)
    • 8.20 Flamel Technologies
    • 8.21 General Electric
    • 8.22 Glaxosmithkline
    • 8.23 Honeywell International
    • 8.24 Invitrogen
    • 8.25 Nano-C
    • 8.26 Nanocyl Sa
    • 8.27 Nanogen, Inc
    • 8.28 Nanolab Systems
    • 8.29 Nanopass Technologies, Ltd
    • 8.30 Nanophase Technologies Corporation
    • 8.31 Nanospectra Biosciences
    • 8.32 Nanosphere, Inc
    • 8.33 Nanosys
    • 8.34 New England Precision Grinding (Nepg)
    • 8.35 Novartis
    • 8.36 Novavax
    • 8.37 Nucryst (Westaim) Pharmaceuticals
    • 8.38 Orthovita
    • 8.39 Phillips
    • 8.40 Psivida Corporation
    • 8.41 Quantum Dot Corporation
    • 8.42 Roche
    • 8.43 Sandvik Bioline
    • 8.44 Starpharma Holdings, Limited
    • 8.45 Sigma Aldrich
    • 8.46 Wyeth Pharmaceuticals
  • 9 Appendix: Nanotechnology References
  • 10 Appendix: Glossary Of Terms In Nanotechnology
    • 10.1 Bionanotechnology
      • 10.1.1 Nanopore Sequencing
      • 10.1.2 Cantilevers With Functionalized Tips
      • 10.1.3 Microneedles
      • 10.1.4 Microchips For Drug Delivery
      • 10.1.5 Nucleic Acid Lattices And Scaffolds
      • 10.1.6 Nanofibers As Biomaterials
      • 10.1.7 Carbon Nanotubes
    • 10.2 Definition Of Nano-Particles With Biological And Medical Applications
      • 10.2.1 Superparamagnetic Iron Oxide Crystals
      • 10.2.2 Quantum Dots
      • 10.2.3 Dendrimers
      • 10.2.4 Polymeric Micelles
      • 10.2.5 Liposomes
      • 10.2.6 Nanospheres
      • 10.2.7 Aquasomes (Carbohydrate-Ceramic Nano-Particles)
      • 10.2.8 Polyplexes/Lipopolyplexes
  • 11 Appendix: Nni Centers And Networks Of Excellence
    • 11.1 National Science Foundation
    • 11.2 Department Of Energy
    • 11.3 Department Of Defense
    • 11.4 National Aeronautics And Space Administration (Nasa)
    • 11.5 National Institute For Occupational Safety And Health
    • 11.6 National Institute Of Standards And Technology
    • 11.7 National Institutes Of Health
  • List Of Figures
    • Figure 2.1: End-User Markets For Nanotechnology, 2007
    • Figure 2.2: Nanometer Scale
    • Figure 2.3: International Per Capita Healthcare Spending By Country, 2006
    • Figure 2.4: World Nanomedical Market Shares, 2007
    • Figure 2.5: Total Spending On Healthcare In The U.S., 1960 To 2007
    • Figure 3.1: Nanotechnology Applications
    • Figure 3.2: Carbon Nanotubes
    • Figure 4.1: Depiction Of Nab Technology
    • Figure 7.1: Fda Product Validation Chart
    • Figure 7.2: Fda Product Lifecycle Model
    • Figure 8.1: Sigma Aldrich Sales Distribution
  • List Of Tables
    • Table 2.1: Global Market For Nanotechnology Products, 2005 To 2013
    • Table 2.2: Nanotechnology Materials For Consumer Products, 2005 To 2013
    • Table 2.3: Nanotechnology Markets Worldwide By Industry, 2002 To 2015
    • Table 2.4: Nanotechnology Development Worldwide By Region, 2002 To 2015
    • Table 2.5: Currently-Growing Nanofabrication Techniques
    • Table 2.6: Global Nanomedicine Market, 2004 To 2013
    • Table 2.7: Nanomedicine Market Revenues By Product Segment, 2007
    • Table 2.8: Global Nanomedicine Market By Geographic Segment, 2004 To 2013
    • Table 2.9: U.S. Nanomedicine Market, 2004 To 2013
    • Table 2.10: European Nanomedicine Market, 2004 To 2013
    • Table 2.11: Japanese Nanomedicine Market, 2004 To 2013
    • Table 2.12: Japanese Nanotechnology Product Market Forecast
    • Table 2.13: Government Funding For Nanotechnology Research And Development, 1997 To 2008
    • Table 2.14: Global Nanotechnology R&d Spending, 1997 To 2013
    • Table 2.15: Global Growth In Nanotechnology R&d, 1997 To 2013
    • Table 3.1: Global Market For Nanotechnology Applications In The Life Sciences, 2005 To 2012
    • Table 3.2: Market For Nano-Particles In Life Sciences And Medicine, 2004 To 2012
    • Table 3.2: Market For Nanostructured Materials In Life Sciences And Medicine, 2004 To 2012
    • Table 3.4: Market For Nanodevices In Life Sciences And Medicine, 2004 To 2012
    • Table 3.5: Commercial Applications Of Quantum Dots
    • Table 3.6: Market For Nanocomposites In Life Sciences And Medicine, 2004 To 2012
    • Table 3.7: Liposomal Formulations Used In Nanotechnology
    • Table 3.8: Types Of Nanoparticulate Drug Delivery Systems
    • Table 4.1: Fda-Approved Drugs Developed With Nanotechnology-Based Formulations
    • Table 4.2: Key Effectors Of Drug Delivery Using Nanomaterials
    • Table 4.3: Nanoscale Applications For Drug Delivery In Pharmaceutical Drug Development
    • Table 4.4: Drug Delivery Nanotechnology Market Drivers Ranked In Order Of Impact
    • Table 4.5: Drug Delivery Nanotechnology Market Restraints Ranked In Order Of Impact
    • Table 4.6: Anti-Cancer Drugs Formulated Using Nanomaterials
    • Table 4.7: Nanomaterials For In Vitro Rnai Delivery
    • Table 4.8: Use Of Peptide-Based Nanotubes For Biological Active Targets
    • Table 4.9: Lab-On-Chip And Microfluidic Chip Technology Innovations
    • Table 4.10: Diagnostic Nanotechnology Market Drivers Ranked In Order Of Impact
    • Table 4.11: Diagnostic Nanotechnology Market Restraints Ranked In Order Of Impact
    • Table 4.12: Fda-Approved In Vivo Imaging Materials Developed With Nanotechnology-Based Formulations
    • Table 4.13: Application Areas For Phage Nanotechnology Platforms
    • Table 4.14: Application Areas For Neuroscience Nanotechnology Platforms
    • Table 4.15: Nanotechnology Application Areas For Medical Nanomaterials
    • Table 4.16: Fda-Approved Dental Biomaterials Developed With Nanotechnology-Based Formulations
    • Table 4.17: Drug Discovery Nanotechnology Market Drivers Ranked In Order Of Impact
    • Table 4.18: Drug Discovery Nanotechnology Market Restraints Ranked In Order Of Impact
    • Table 4.19: Examples Of Proposed U.S. Nni Interagency Collaborative Activities
    • Table 5.1: Medical Nanotechnology Market Driversglobal, 2008 To 2016
    • Table 5.2: Medical Nanotechnology Market Restraintsglobal, 2008 To 2016
    • Table 5.3: U.S. Nanotechnology Patents Issued Per Year, 1996 To 2006
    • Table 5.4: Sources Of Nanotechnology Funds
    • Table 5.5: National Government Funding Leaders For Nanotechnology, 2007
    • Table 5.6: Total Investments In Venture-Backed Nanotechnology Companies, 1997 To 2008
    • Table 5.7: Leading Nanotechnology Start-Up Companies
    • Table 6.1: Summary Of Key Advantages For Nanotechnology
    • Table 6.2: Nanotechnology Platforms Used For Diagnostics And Imaging
    • Table 6.3: Fda-Approved In Vitro Diagnostics Developed With Nanotechnology-Based Formulations
    • Table 6.4: Applications Of Veridex Nanotechnology Platform For Diagnostic Assays
    • Table 6.5: Characteristics Of Gold Nano-Particle Technology For Diagnostic Testing
    • Table 6.6: Overview Of Future Nanomedical Technology Development
    • Table 6.7: Recent Developments In Nanotechnology For Drug Delivery And Drug Discovery
    • Table 6.8: Recent Developments In Nanomaterials And Nanotechnology-Based Devices
    • Table 6.9: Recent Nanotechnology Applications In Diagnostics
    • Table 6.10: Future Nanomedical Technology Platforms
    • Table 6.11: Additional Global Market Trends
    • Table 8.1: Amag Nanotechnology Products And Candidates